8-K: Bristol Myers Squibb to Acquire 2seventy bio for $286 Million, Offering $5.00 Per Share

Bristol Myers Squibb will acquire 2seventy bio in an all-cash transaction for $5.00 per share, valuing the company at approximately $286 million.

Summary

• Bristol Myers Squibb (BMS) will acquire 2seventy bio for $5.00 per share in cash.
• The total equity value of the transaction is approximately $286 million, or $102 million net of estimated cash.
• The offer represents an 88% premium to 2seventy bio's closing price on March 7, 2025.
• BMS will commence a tender offer to acquire all outstanding shares of 2seventy bio.
• 2seventy bio's Board of Directors unanimously recommends stockholders tender their shares.
• The transaction is expected to close in the second quarter of 2025, pending customary closing conditions.
• Following the tender offer, BMS will acquire any remaining shares through a second-step merger at $5.00 per share.
• Certain 2seventy bio stockholders, owning approximately 5.3% of outstanding shares, have agreed to tender their shares.
• Goldman Sachs & Co. LLC is serving as 2seventy bio's financial advisor, and Goodwin Procter LLP is legal counsel.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the acquisition at a premium, indicating a favorable outcome for 2seventy bio's shareholders. The deal is expected to benefit the continued development of Abecma.

Positives

• The acquisition provides 2seventy bio stockholders with an 88% premium over the recent closing price.
• BMS's resources and experience are expected to benefit the continued development and delivery of Abecma to patients.
• The all-cash transaction provides certainty of value to 2seventy bio stockholders.
• The transaction has the unanimous support of 2seventy bio's Board of Directors.

Risks

• The transaction is subject to customary closing conditions, including regulatory approvals.
• There is a risk that the expected benefits and synergies of the acquisition may not be realized.
• Legal proceedings could be instituted related to the merger agreement.
• Competing offers or acquisition proposals for 2seventy bio could emerge.
• Various conditions to the consummation of the tender offer or the acquisition may not be satisfied or waived.
• Unanticipated difficulties or expenditures relating to the proposed acquisition could arise, including difficulties in employee retention.

Future Outlook

The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.

Management Comments

• Chip Baird, chief executive officer of 2seventy bio, stated that the acquisition represents the culmination of the journey for 2seventy bio and that Abecma will continue to benefit from BMS's experience and resources.

Industry Context

This acquisition reflects ongoing consolidation in the biotechnology industry, with larger pharmaceutical companies acquiring smaller firms to expand their pipelines and product portfolios, particularly in specialized areas like cell and gene therapy.

Comparison to Industry Standards

• The 88% premium offered by Bristol Myers Squibb is above average compared to recent acquisitions in the biotech industry, where premiums typically range from 20% to 50%.
• Comparable transactions include Gilead's acquisition of Kite Pharma and Novartis' acquisition of AveXis, both focused on innovative therapies.
• The valuation of approximately $286 million is relatively small compared to other major pharmaceutical acquisitions, reflecting 2seventy bio's focus on a single key asset (Abecma).

Stakeholder Impact

• Shareholders will receive a premium for their shares.
• Employees may experience changes in their roles and responsibilities following the acquisition.
• Patients are expected to benefit from BMS's resources and experience in delivering Abecma.
• Partners and suppliers may see changes in their relationships with the company.

Next Steps

• BMS will promptly commence a tender offer to acquire all outstanding shares of 2seventy bio.
• 2seventy bio stockholders are expected to tender their shares in the tender offer.
• The companies will work to satisfy customary closing conditions, including regulatory approvals.
• Following the tender offer, BMS will acquire any remaining shares through a second-step merger.

Key Dates